Multiple Sclerosis: Selections from "The World Market for Neurotherapeutic Drugs"

 
   Single User - $1,121
   Hard Copy Mail Delivery - $1,121
   Corporate License - $2,242
   Online Download plus 1 Hard Copy - $1,421


Loading...
Published Sep 1, 2002 | 158 Pages | Pub ID: KLI802164

Special Offer. Now 25% off the original price of $1495.
In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resultant report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad therapeutic category as a whole.

Therefore, Kalorama is now offering selections from the neurotherapeutics study, covering each of these topics in turn, while at the same time providing selected overall findings in other disease areas to allow for comparison and context. The selections provide the study’s full results in the specific area and the general context and strategic implications from the full study, all at a fraction of the cost.

Among the selections, you’ll find:

I. Executive Summary (15 pages) —Included in this selection is the complete executive summary from the full neurotherapeutics report, providing you with an overview of the entire neurotherapeutics market and top-level numbers on such neurological diseases as peripheral neuropathy, Parkinson’s disease, and Alzheimer’s disease, among others for the top seven world markets. The executive summary outlines the context of the entire neurology market and how MS therapeutics fit in.

II. Introduction (3 pages) —Selection includes the overview of MS, including prevalence estimates.

III. Treatment (11 pages) —This selection reviews current treatment protocols and the agents used in relapsing-remitting MS, secondary-progressive MS, and other forms of MS.

IV. Progress and Promise in Therapeutic Development (27 pages) —Because progress on other neurotherapeutic fronts can have significant impact on MS therapeutics, information about all of the developments in neurogenomics and neural implants that the full study covered are included in this selection. Information specific to MS includes Table 4-11: Active Clinical Trials Involving Multiple Sclerosis.

V. World Market Analysis (28 pages, including 10 tables and 4 figures) —Selection provides complete market projections and growth rates for MS therapeutics in each of the top world markets. Growth rates for MS markets and those of other major neurological diseases are included, along with total world numbers for comparison.

VI. Company Profiles (31 pages) —Profiles of the following companies are included:

  • Cortex Pharmaceuticals, Inc.
  • Elan Corporation plc
  • Guilford Pharmaceuticals Inc.
  • Neurocrine Biosciences, Inc.
  • Pharmos Corporation

VII. Conclusions and Strategic Implications (9 pages) —This selection represents all of the analyst’s conclusions from the neurotherapeutics study as a whole, spelling out seven main conclusions and what they mean for developers and marketers of neurotherapeutic agents.

VIII. Glossary (8 pages)

IX. Company Directory (8 pages)

Executive Summary
  • Background
  • Scope and Methodology
  • Size and Growth of Market
  • Market Trends

Overview of Neurologic Diseases and Disorders

  • Multiple Sclerosis

Treatment of Neurologic Diseases and Disorders

    Demyelinating Diseases
    • Relapsing-Remitting Multiple Sclerosis
    • Secondary-Progressive Multiple Sclerosis
    • Other Forms of Multiples Sclerosis
    • Other Demyelinating Diseases

Progress and Promise in Therapeutics Development

    Genetics and Neurogenomics

    Neural Implant Technologies

    Miscellaneous Advances

    • Vascular Endothelial Growth Factor (VEGF)
    • Minocycline
    • Stroke and Apoptosis

    Clinical Trial Activity

World Market Analysis

    Background

    The Markets by Geography

    • The United States
    • France
    • Germany
    • Italy
    • Spain
    • United Kingdom
    • Japan

    The Market by Applications

    • Multiple Sclerosis

Company Profiles

  • Cortex Pharmaceuticals, Inc.
  • Elan Corporation plc
  • Guilford Pharmaceuticals Inc.
  • Neurocrine BioSciences, Inc.
  • Pharmos Corporation

Conclusions and Strategic Implications

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion

Glossary

Company Directory

List of Exhibits

  • Table 1-1: Estimated Market Sizes for the Top Five Applications Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
  • Table 1-2: Estimated Market Sizes for the Geographic Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
  • Table 3-1: Comparison of Modern Drugs for the Treatment of Relapsing- Remitting Multiple Sclerosis
  • Table 4-1: Known Genetic Alternation in Neurologic Neoplasms
  • Table 5-1: The Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2001-2010
  • Table 5-2: The Potential for Neurotherapeutics in the United States by Application, 2001-2010
  • Table 5-3: The Potential for Neurotherapeutics in France by Application, 2001-2010
  • Table 5-4: The Potential for Neurotherapeutics in Germany by Application, 2001-2010
  • Table 5-5: The Potential for Neurotherapeutics in Italy by Application, 2001-2010
  • Table 5-6: The Potential for Neurotherapeutics in Spain by Application, 2001-2010
  • Table 5-7: The Potential for Neurotherapeutics in the United Kingdom by Application, 2001-2010
  • Table 5-8: The Potential for Neurotherapeutics in Japan by Application, 2001-2010 82
  • Table 5-9: The Potential for Neurotherapeutics in the Major World Healthcare Markets by Application 2001-2010
  • Table 5-16: The Potential for Multiple Sclerosis Therapeutics in the Major World Healthcare Markets 2001-2010
  • Figure 1-1: Incidence of Major Neurologic Diseases in the Major World Healthcare Markets, 2001-2010
  • Figure 1-2: The Total Market for Neurotherapeutics in the Major World Healthcare Markets, 2001-2010
  • Figure 1-3: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Application, 2001-2009
  • Figure 1-4: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Geographic Region, 2001-2009
  • Figure 1-5: Composition of the Markets for Neurotherapeutics by Applications Segment, 2002 and 2010
  • Figure 1-6: Composition of the Markets for Neurotherapeutics by Geographic Segment, 2002 and 2010
  • Figure 2-1: Structure of the Normal Motor Neuron
  • Figure 4-1: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 1-4
  • Figure 4-2: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 5-8
  • Figure 4-3: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 9-12:
  • Figure 4-4: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 13-16
  • Figure 4-5: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 17-20
  • Figure 4-6: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 21, 22, X, and Y
  • Figure 5-1: Growth Rates in Neurotherapeutics Potential for the Seven Major World Healthcare Markets, 2001-2010
  • Figure 5-2: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2002
  • Figure 5-3: Growth Rates in Neurotherapeutics Market Opportunities 2001-2010
  • Figure 5-4: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets by Application, 2002

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.